The company is scheduled to start two phase 2 trials for its lead asset, with first results expected in mid-2023. Investors, with high-risk appetite can go for this stock ahead of key milestones.
- Innate Immunotherapeutics (ATX AU) is an Australian pharmaceutical company advancing a pipeline of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis.
- The company’s primary focus for 2022 is on initiating phase 2 clinical trials in pancreatic cancer and, in the second half of the year in lung fibrosis.
- With latest quarter’s cash burn of AUD0.94 million and cash balance of AUD16.2 million, the company is well-positioned to fund its near-term R&D activities.
By Tina Banerjee - https://www.smartkarma.com/profiles/tina-banerjee?utm_source=tiger_community
On Innate Immunotherapeutics (ATX AU) - https://www.smartkarma.com/entities/amplia-therapeutics-ltd?utm_source=tiger_community
Comments